ClinicalTrials.gg
RecruitingNCT07569055Updated May 6, 2026

Longitudinal Cohort Study on Invasive Fungal Disease After Allogeneic Hematopoietic Stem Cell Transplantation

An observational study in Invasive Fungal Disease and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT), sponsored by Peking University People's Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Peking University People's Hospital · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
6,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Invasive Fungal Infections with a site in China — 12 open to participants now, 12 under way, none of them phase 3. Invasive Fungal Infections · China.

Planned enrollment
Largest of 17
6,000 · median 120
Started
2025
with 6 others
Observational
17 of 29
10 open now
Primary completion
2031-03
later than 11 of 11 live
Registered
24th of 29
by date
Lead sponsor
2 of 29
Peking University People's Hospital

Among the 29 studies in Invasive Fungal Infections with a site in China, this one has the largest planned enrollment of the 17 observational ones that give a count, is one of 7 that started in 2025, is one of 17 observational ones, reaches primary completion later than 11 of the 11 other live ones, and was the 24th registered.

Invasive Fungal Infections

136 studies on the registry are indexed under Invasive Fungal Infections; 33 are open to participants now.

Browse Invasive Fungal Infections studies →

Open to participants now

12 of the 29 studies in Invasive Fungal Infections with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 20 Invasive Fungal Infections studies recruiting now, 12 (60%) set no upper age limit and 5 (25%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Invasive Fungal Infections with a site in China, or all of them as a file.
02

Study summary

Invasive fungal disease (IFD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), characterized by high incidence and high mortality. According to the data from a multi-center study in China (CAESAR 2.0), even with the extensive use of antifungal active drugs for prevention, the cumulative incidence of IFD one year after HSCT still reached 6.3%, and the IFD-related mortality rate was 48.28%. In recent years, with the improvement of transplantation techniques, the application of new antifungal drugs and the optimization of diagnostic methods, the pathogen spectrum and clinical characteristics of IFD have undergone significant changes. Compared with ten years ago, the proportion of non-Aspergillus pathogens (such as Candida and Mucophora) has significantly increased, while the proportion of Aspergillus has relatively decreased. In addition, different types of invasive mycosis (such as invasive aspergillosis and invasive fusarium) show significant differences in clinical manifestations, onset time and prognosis. However, at present, large-scale prospective cohort studies on IFD after HSCT in China are still relatively scarce, and the diagnosis and treatment norms and prevention strategies in clinical practice still need to be further optimized. This study intends to conduct a multi-center retrospective and prospective combined longitudinal cohort study to comprehensively register the basic information, diagnosis, treatment and prognosis of IFD patients after HSCT, providing evidence-based medical basis for establishing new clinical diagnosis and treatment technologies and improving the long-term survival rate of patients.

Read the detailed description

Invasive fungal disease refers to a severe infection caused by fungi invading human tissues, blood or body fluids, mainly affecting people with weakened immune systems. Under the background of HSCT, due to the transplantation recipients undergoing high-dose chemotherapy pretreatment, graft-versus-host disease (GVHD), and the use of immunosuppressants, the immune function of the body is severely impaired, and the risk of IFD occurrence significantly increases. The clinical manifestations of IFD after HSCT are diverse, which can involve multiple organs and systems such as the lungs, blood, central nervous system, and skin. It is difficult to diagnose, challenging to treat, and has a poor prognosis, seriously affecting the long-term survival and quality of life of transplant patients.

In recent years, the epidemiological characteristics of IFD after HSCT have undergone significant changes. According to the CAESAR 2.0 study, among 2015 Chinese patients who received allo-HSCT, the cumulative one-year incidence of IFD (proven + probable) was 6.3%. It is worth noting that compared with the CAESAR study ten years ago, the pathogen spectrum has undergone a significant transformation, which is closely related to the evolution of antifungal prevention strategies - ten years ago, fluconazole was mainly used for prevention, while currently about three quarters of patients use antifungal active drugs such as voliconazole or posaconazole. Although this shift in preventive strategies has reduced the occurrence of aspergillosis, it may increase the risk of infection from drug-resistant pathogens such as Mucor.

IFD after HSCT remains a major clinical challenge affecting the prognosis of patients. The current research has the following deficiencies: (1) There is still a lack of multi-center, large-sample prospective cohort studies in China; (2) The dynamic changes in the pathogen spectrum and clinical characteristics of IFD require continuous monitoring. (3) The diagnosis and treatment strategies and prognostic factors of different types of IFD need in-depth research. Based on the above background, this study intends to establish a longitudinal observational cohort that combines retrospective and prospective approaches to systematically evaluate the epidemiological characteristics, treatment strategies, and short-term and long-term outcomes of IFD patients after HSCT.

03

Conditions studied

  • Invasive Fungal Disease
  • Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Keywords

  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Invasive Fungal Disease
  • Prediction
  • Prognosis
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Study population:

Patients who underwent allo-HSCT at Peking University People's Hospital and other assistance centers since January 1, 2014.

Outcome Assessment:

Patients were followed up for the development of invasive fungal disease (IFD) after transplantation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Since January 1, 2014, patients who underwent at Peking University People's Hospital and other assistance centers.

Exclusion criteria

Exclusion Criteria:

  1. For any reason, such as the occurrence of severe mental disorders, the follow-up information may be unavailable;
  2. Patients deemed unsuitable for the study by the researchers.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
6,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Retrospective cohort

    Patients whose first visit to our institution and the termination of follow-up both occurred before the opening of this study will contribute to the retrospective cohort.

  • Prospective cohort

    Patients whose first visit to our institution occur after the opening of this study will contribute to the prospective cohort.

  • Retrospective/Prospective cohort

    Patients whose first visit to our institution occurred before the opening of this study and whose follow-up will terminate after the opening of this study will contribute to the ambispective cohort.

06

What researchers measure

Primary outcomes

  1. Overall survival after allo-HSCT, measured as time from transplantation to death from any cause

    Overall survival is defined as the time from the date of allogeneic hematopoietic stem cell transplantation to death from any cause. Participants without documented death will be censored at the date of last contact or at 5 years after transplantation, whichever occurs first. Overall survival probabilities at 1, 3, and 5 years after transplantation will be estimated using the Kaplan-Meier method.

    Time frame: From date of allo-HSCT to death, last contact, or 5 years after allo-HSCT, whichever occurs first

Secondary outcomes

  1. Proportion of participants with invasive fungal disease who have overall response at 1 year

    Overall response of invasive fungal disease is defined as complete response or partial response at 1 year after diagnosis of invasive fungal disease. Response will be assessed according to the Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria for treatment response in invasive fungal diseases. Participants who die before the 1-year assessment or do not meet complete or partial response criteria will be classified as not having overall response. The outcome will be summarized as the number and percentage of participants with complete or partial response.

    Time frame: 1 year after diagnosis of invasive fungal disease

  2. Cumulative incidence of proven or probable invasive fungal disease within 1 year after allo-HSCT

    Invasive fungal disease is defined as the first episode of proven or probable invasive fungal disease after allo-HSCT according to protocol-defined diagnostic criteria based on EORTC/MSGERC definitions. Death before invasive fungal disease will be treated as a competing event. Participants who do not develop invasive fungal disease and do not die will be censored at the date of last contact or at 1 year after allo-HSCT, whichever occurs first. The cumulative incidence function will be used to estimate the incidence of invasive fungal disease.

    Time frame: From date of allo-HSCT to first diagnosis of invasive fungal disease, death, last contact, or 1 year after allo-HSCT, whichever occurs first

  3. Number and percentage of participants with post-transplant complications within 5 years after allo-HSCT

    Post-transplant complications include acute graft-versus-host disease, chronic graft-versus-host disease, cytomegalovirus infection or reactivation, Epstein-Barr virus infection or reactivation, bacterial bloodstream infection, organ dysfunction, relapse of the underlying hematologic disease, graft failure, intensive care unit admission. The outcome will be summarized as the number and percentage of participants with at least one post-transplant complication and by complication category.

    Time frame: From date of allo-HSCT to death, last contact, or 5 years after allo-HSCT, whichever occurs first

  4. Number and percentage of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Treatment-related adverse events are adverse events considered related to systemic antifungal therapy. Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The outcome will be summarized as the number and percentage of participants with at least one treatment-related adverse event. Grade 3 or higher adverse events and serious adverse events will be summarized separately.

    Time frame: From initiation of systemic antifungal therapy to 30 days after the last dose, death, or last contact, whichever occurs first

  5. Total length of hospital stay within 5 years after allo-HSCT, measured in inpatient days

    Total length of hospital stay is defined as the cumulative number of inpatient days recorded for each participant after allogeneic hematopoietic stem cell transplantation and before death, last contact, or 5 years after transplantation, whichever occurs first. The outcome will be summarized as inpatient days per participant using descriptive statistics.

    Time frame: From date of allo-HSCT to death, last contact, or 5 years after allo-HSCT, whichever occurs first.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2031, 71 months after the start.

Of 30 observational studies under Invasive Fungal Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's planned 71 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2026
First posted
May 6, 2026
StartActual
Mar 15, 2025
Primary completionEst.
Mar 14, 2031
CompletionEst.
Mar 14, 2031
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07569055
Collaborators
First Affiliated Hospital of Guangxi Medical University, First Affiliated Hospital of Harbin Medical University, The First Hospital of Jilin University, Jining Medical University, Qianfoshan Hospital, Shandong Provincial Hospital, Shanxi Province Cancer Hospital, Shengjing Hospital, First Affiliated Hospital of Xinjiang Medical University, Zhejiang University, The General Hospital of Northern Theater Command
Responsible party
Xiao Hui Zhang (Vice President of Peking University Institute of Hematology Affiliation: Peking University People's Hospital, Peking University People's Hospital) — Principal investigator
First posted
May 6, 2026
Start date
Mar 15, 2025
Primary completion
Mar 14, 2031 (estimated)
Completion
Mar 14, 2031 (estimated)
Last update
May 6, 2026

Study contacts

Jin Wu, MD
Contact
wujin1996@126.com
086-01088326002
Fanhao Nie
Contact
Niefh2003@163.com
086-18887323790
Xiao-Hui Zhang, MD
principal investigator · Peking University Institute of Hematology, Peking University People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion